Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK ® • Company halting further development of AlloNK ® (AB-101), including the planned phase 3 pivotal trial • Updated deep B cell depletion and clinical response data is consistent
Artiva Biotherapeutics (ARTV) is halting development of AlloNK® (AB-101) due to safety concerns and insufficient long-term efficacy data. The company will cut 94% of its workforce and explore strategic alternatives, including potential mergers or liquidation. Artiva had $319.1M in cash as of September 30, 2026.
Aslan Fred (Chief Executive Officer) sold 61,696 shares of Artiva Biotherapeutics, Inc. (ARTV) at $6.84 ($0.42M total) on 2026-10-05.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning ARTV (Artiva Biotherapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 6 bearish.
Recent ARTV coverage spans financial news, corporate actions and insider activity.
In the last 30 days, ARTV insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($726K). The most active reporter was Aslan Fred, Chief Executive Officer, with 2 filings. 20% of those filings were made under pre-arranged Rule 10b5-1 plans.
The discontinuation removes the company's lead asset, likely triggering a sharp sell‑off.
The halt of a lead cell‑therapy program and massive layoff signal a severe setback for the company.
The insider sale may create modest selling pressure on ARTV.
The announcement may generate modest buying interest ahead of the data release.
Positive Phase 2 data may boost investor confidence and drive the stock higher.
AlphAI scores every news story that mentions ARTV with an AI model for sentiment and relevance, and aggregates insider trades from Artiva Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK ® • Company halting further development of AlloNK ® (AB-101), including the planned phase 3 pivotal trial • Updated deep B cell depletion and clinical response data is consistent
2 min readArtiva Biotherapeutics (ARTV) is halting development of AlloNK® (AB-101) due to safety concerns and insufficient long-term efficacy data. The company will cut 94% of its workforce and explore strategic alternatives, including potential mergers or liquidation. Artiva had $319.1M in cash as of September 30, 2026.
2 min readAslan Fred (Chief Executive Officer) sold 61,696 shares of Artiva Biotherapeutics, Inc. (ARTV) at $6.84 ($0.42M total) on 2026-10-05.
1 min readArtiva Biotherapeutics (NASDAQ:ARTV) will present clinical data from its AlloNK program at ACR Convergence 2026, including updated data from 20+ patients with refractory rheumatoid arthritis, 11 with Sjögren disease, and 5 with systemic sclerosis. The company plans to initiate a Phase 3 trial for AlloNK in refractory rheumatoid arthritis in the second half of 2026.
1 min readH.C. Wainwright reiterated a Buy rating and $35 price target on Artiva Biotherapeutics (ARTV). The stock has risen 130% in the past year, trading at $6.79. Analysts cite undervaluation and positive clinical data for Sjögren’s disease treatment. The firm sees potential for rheumatoid arthritis trial success in 2026.
2 min readCantor Fitzgerald maintained an Overweight rating and $40 price target for Artiva Biotherapeutics, implying a 489.1% upside from the Oct 1 close. The firm cited strong early efficacy data and a favorable safety profile for Artiva's AlloNK therapy, which showed improvements in symptoms and lacked severe adverse events.
1 min readArtiva Biotherapeutics (ARTV) reported Phase 2a data for AlloNK in Sjögren disease, showing improvements in disease activity and symptoms in 11 patients. Mean salivary flow increased from 0.4 to 1.1 mL/min in 8 patients. Safety data across 73 patients showed no severe adverse events, supporting outpatient administration. The company plans to initiate a Phase 3 rheumatoid arthritis trial in H2 2026.
1 min readArtiva Biotherapeutics (ARTV) presented updated data on AlloNK® (AB-101) for Sjögren disease at ISSjD 2026. 11 patients showed improvements in disease activity and symptoms, with mean stimulated salivary flow increasing from 0.4 to 1.1 mL/min. Safety data from 73 patients showed no severe adverse events, supporting outpatient administration. The company plans a Phase 3 trial for refractory rheumatoid arthritis in 2026.
3 min readArtiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On September 8, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Me
1 min readHoran Christopher (Chief Tech Operations Officer) sold 10,366 shares of Artiva Biotherapeutics, Inc. (ARTV) at $11.16 ($0.12M total) on 2026-09-03.
1 min read
